Norway· NO-ID_4C5F7266-D5DC-4746-8972-74E73985720D

RoActemra

A tocilizumab product containing tocilizumab, registered in Norway by Roche Registration GmbH. The same ATC class is registered in 15 of our 19 countries.

ATC L04AC07

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedRoActemraATCL04AC07REGISTER NO.NO-ID_4C5F7266-D5DC-4…PACKS LISTED3CHECKEDSeptember 25, 2026

Where it is registered

Tocilizumab is registered in 15 of 19 countries.

Countries holding a registration under ATC L04AC07 (tocilizumab), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 9 of them publish a price we can compare per daily dose

Tocilizumab · ATC L04AC07

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tocilizumab costs, country by country.

Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Tocilizumab · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$29.63
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FEST (Norway)
Active substance
Tocilizumab
Manufacturer
Roche Registration GmbH
Country
Norway (NO)
ATC code
L04AC07
ATC class
Tocilizumab
Defined daily dose
20 mg, P
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • no_merkevare_id
    ID_4C5F7266-D5DC-4746-8972-74E73985720D
  • no_varenummer
    063926
    4 x 0.9
    NOK 9857.9
  • gtin
    7613326006354

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

263 interactions on record for tocilizumab.

Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Tocilizumab · interactions on record

263 records

  • 38 severe
  • 218 moderate
  • 7 minor

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • CladribineL01BB04severe
  • PexidartinibL01EX15severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tocilizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tocilizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Tofidence
  • Iceland · Avtozma, Roactemra
  • Liechtenstein · Avtozma, Roactemra

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d6843d72-d790-4ee8-bfe6-87045229c145
GET /v1/drugs/d6843d72-d790-4ee8-bfe6-87045229c145?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Injeksjonsvæske, oppløsning i ferdigfylt sprøyte",
  "source": "fest",
  "status": "A",
  "atc_name": "Tocilizumab",
  "merkevare_id": "ID_4C5F7266-D5DC-4746-8972-74E73985720D",
  "name_form_strength": "RoActemra inj, oppl 162 mg/sprøyte",
  "prescription_group": "C"
}

See everything about tocilizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.